Search the site

Research

Cyclophosphamide chemotherapy sensitizes tumor cells to TRAIL-dependent CD8 T cell-mediated immune attack resulting in suppression of tumor growth

Anti-cancer chemotherapy can be simultaneously lymphodepleting and immunostimulatory.

People

Associate Professor Raelene Endersby

Co-Head, Brain Tumour Research

News & Events

Researchers unlock potential new cancer weapon

In an exciting breakthrough for cancer treatment, a new weapon to enable the immune system to combat the disease may have been unlocked.

News & Events

Global war on brain cancer

Dr Nick Gottardo and Dr Raelene Endersby from The Kids Research Institute Australia are the driving force behind an innovative, global action group on child brain cancer.

News & Events

Study finds folate protects against childhood brain tumours

A national study led by Perth's Telethon Institute has found that folic acid supplements before and during pregnancy reduces the risk of childhood brain tumours

News & Events

New insight into treatment options for rare childhood brain tumour, 2011 Media Release, Telethon Institute for Child Health Research

A new study led by Australian researchers has outlined for the first time the best treatment options for children suffering from meningioma

News & Events

Continuing the cancer fight

Work by the Institute's Division of Children's Leukaemia and Cancer Research has been recognised with three research grants from the Cancer Council of WA.

News & Events

Apache Energy joins Telethon Institute in cancer research partnership

Apache Energy and the Telethon Institute for Child Health Research today signed a two-year partnership

Research

Leukaemia

Leukaemia, also spelled leukemia, is a cancer that develops in the bone marrow and results in abnormal white blood cells. It is the most common cancer in children, accounting for almost a third of all childhood & teen cancers.

Research

SNO-EANO-EURACAN consensus on management of pineal parenchymal tumors

Pineal parenchymal tumors are rare neoplasms for which evidence-based treatment recommendations are lacking. These tumors vary in biology, clinical characteristics, and prognosis, requiring treatment that ranges from surgical resection alone to intensive multimodal antineoplastic therapy.